Global Allergy Leader Stallergenes Greer is a leading global biopharmaceutical company focused on allergen immunotherapy with products and services available in 45 countries, indicating a broad international footprint suitable for cross-border sales opportunities and partner expansion.

Growth through Expansion Recent news highlights investments and expansion of manufacturing facilities in France and Western Europe, plus acquisition activity to boost venom immunotherapy production, signaling capacity growth and potential demand for clinical and supply chain services, equipment, and contract manufacturing collaborations.

Strong Financial Health Reported revenue in the high hundreds of millions with substantial funding, underscoring a sizeable market presence and potential for larger-scale deals, multi-year partnerships, and co-development opportunities in immunotherapy therapies.

Clinical Evidence Momentum Active participation in EAACI 2026 and presentation of new long-term outcome data position the company as a source of innovative clinical evidence, creating opportunities for advisory, data analytics, and real-world evidence collaborations or sponsored research partnerships.

Strategic Acquisitions Acquisition of Entomon s.r.l. and expansion of venom immunotherapy production indicate a strategy to broaden product capabilities and manufacturing capacity, suggesting opportunities for suppliers, equipment providers, and integration partners to support scale-up and GMP-compliant operations.